patient subgroup...
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
mNSCLC - L2 - EGFR mutant, anti-PD-(L)1 , meta-analysis of study results
Outcome
Relative effect 95%CI
LoD
Trt. better when
I2
k (RCT/OBS)
Bayesian probability
Overall ROB
Publication bias
Degree of certainty
Endpoint importance
Published MA
efficacy endpoints 00 deaths (OS) 2.60 [0.39, 17.16]< 1 0% 1 study (1/-) 16.2 % NA not evaluable crucial - progression or deaths (PFS) 1.10 [0.22, 5.61]< 1 0% 1 study (1/-) 45.5 % NA not evaluable important - objective responses (ORR) 0.45 [0.08, 2.40]> 1 0% 1 study (1/-) 17.6 % NA not evaluable non important - safety endpoints 00 AE (any grade) 1.43 [0.03, 77.69]< 1 0% 1 study (1/-) 43.1 % NA not evaluable non important - AE (grade 3-4) 12.38 [1.29, 118.34]< 1 0% 1 study (1/-) 1.5 % NA not evaluable non important - AE leading to death (grade 5) 0.70 [0.01, 37.74]< 1 0% 1 study (1/-) 56.9 % NA not evaluable non important - SAE (any grade) 1.64 [0.32, 8.45]< 1 0% 1 study (1/-) 27.9 % NA not evaluable non important - STRAE (any grade) 0.33 [0.01, 10.81]< 1 0% 1 study (1/-) 72.9 % NA not evaluable non important - TRAE (any grade) 2.33 [0.41, 13.17]< 1 0% 1 study (1/-) 17.0 % NA not evaluable non important - TRAE (grade 3-4) 7.08 [0.34, 148.71]< 1 0% 1 study (1/-) 10.7 % NA not evaluable non important - AE (grade 3-4) endpoints 00 Arthralgia AE (grade 3-4) 0.70 [0.01, 37.74]< 1 0% 1 study (1/-) 56.9 % NA not evaluable non important - Back pain AE (grade 3-4) 0.70 [0.01, 37.74]< 1 0% 1 study (1/-) 56.9 % NA not evaluable non important - Constipation AE (grade 3-4) 0.70 [0.01, 37.74]< 1 0% 1 study (1/-) 56.9 % NA not evaluable non important - Cough AE (grade 3-4) 0.70 [0.01, 37.74]< 1 0% 1 study (1/-) 56.9 % NA not evaluable non important - Diarrhoea AE (grade 3-4) 1.44 [0.04, 46.58]< 1 0% 1 study (1/-) 42.0 % NA not evaluable non important - Dry skin AE (grade 3-4) 0.70 [0.01, 37.74]< 1 0% 1 study (1/-) 56.9 % NA not evaluable non important - Dyspnoea AE (grade 3-4) 0.70 [0.01, 37.74]< 1 0% 1 study (1/-) 56.9 % NA not evaluable non important - Nausea AE (grade 3-4) 0.70 [0.01, 37.74]< 1 0% 1 study (1/-) 56.9 % NA not evaluable non important - Neutropenia AE (grade 3-4) 3.07 [0.13, 74.70]< 1 0% 1 study (1/-) 24.9 % NA not evaluable non important - Pneumonia AE (grade 3-4) 3.07 [0.13, 74.70]< 1 0% 1 study (1/-) 24.9 % NA not evaluable non important - Pruritus AE (grade 3-4) 0.70 [0.01, 37.74]< 1 0% 1 study (1/-) 56.9 % NA not evaluable non important - Rash AE (grade 3-4) 0.70 [0.01, 37.74]< 1 0% 1 study (1/-) 56.9 % NA not evaluable non important - Stomatitis AE (grade 3-4) 0.70 [0.01, 37.74]< 1 0% 1 study (1/-) 56.9 % NA not evaluable non important -
LoD: level of statistical demonstration: Statistically conclusive: statistically significant with a strict control of overall risk of type 1 error (statistically demonstrated), does not take into account the risk of bias;
suggested: nominally statistically significant but without a strict control of overall risk of type 1 error;
inconclusive: not nominally statistically significant;
safety concerns;
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies;
published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE.
Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.